Replies to post #227036 on Biotech Values

[DewDiligence]

FDA approves Tecentriq/Avastin in 1L-HCC:

https://www.businesswire.com/news/home/20200529005593/en

The approval is based on the IMbrave150 study, where Tecentriq/Avastin bested Nexavar monotherapy on OS (HR=0.58) and PFS (HR=0.59).

HCC is an indication where checkpoint inhibitors have not done especially well compared to most other solid tumors.